Advanced search
Publication Cover
Redox Report
Communications in Free Radical Research
Volume 7, 2002 - Issue 4
Submit an article Journal homepage
1,532
Views
143
CrossRef citations to date
0
Altmetric
Reviews

Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease

Gilles J. GuilleminCentre for Immunology and Department of Neurology St Vincent's Hospital and University of New South Wales , Sydney, Australia
&
Bruce J. BrewCentre for Immunology and Department of Neurology St Vincent's Hospital and University of New South Wales , Sydney, Australia
Pages 199-206 | Published online: 02 Dec 2013

  • Heyes MP. The kynurenine pathway and neurologic disease. Therapeutic strategies. Adv Exp Med Biol 1996; 398: 125–129.
  • Stone TW. Endogenous neurotoxins from tryptophan. Toxicon 2001; 39: 61–73.
  • Stone TW. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 1993; 45: 309–379.
  • Curzon G. Brain tryptophan. Normal and disturbed control. Adv Exp Med Biol 1996; 398: 27–34.
  • Bender DA, McCreanor GM. The preferred route of kynurenine metabolism in the rat. Biochim Biophys Acta 1982; 717: 56–60.
  • Botting NP. Chemistry and neurochemistry of the kynurenine path-wayof tryptophan metabolism. Chem Soc Rev 1995;24: 401–412.
  • Moroni F. Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Eur J Pharmacol 1999; 375: 87–100.
  • Lapin IP, Prakhie IB, Kiseleva IP. Excitatory effects of kynurenine and its metabolites, amino acids and convulsants administered into brain ventricles: differences between rats and mice. J Neural Transm 1982; 54: 229–238.
  • Eastman CL. Cytotoxicity of 3-hydroxykynureninein a neuronal hybrid cell line. Brain Res 1989; 495: 225–231.
  • Moroni F, Cozzi A, Peruginelli F, Carpenedo R, Pellegrini-Giampietro DE. Neuroprotective effects of kynurenine-3-hydroxylase inhibitors in models of brain ischemia. Adv Exp Med Biol 1999; 467: 199–206.
  • Melillo G, Bosco MC, Musso T, Varesio L. Immunobiology of picolinic acid. Adv Exp Med Biol 1996; 398: 135–141.
  • Schwarcz R, Whetsell Jr WO, Mangano RM. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 1983;219: 316–318.
  • Stone TW, Perkins MN. Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol 1981; 72:411–412.
  • Kerr SJ, Armati PJ, Brew BJ. Neurocytotoxicity of quinolinic acid in human brain cultures. J Neurovirol 1995; 1: 375–380.
  • Tavares RG, Tasca CI, Santos CE, Wajner M, Souza DO, Dutra-Filho CS. Quinolinic acid inhibits glutamate uptake into synaptic vesicles from rat brain. Neuroreport 2000; 11: 249–253.
  • Rios C, Santamaria A. Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. Neurochem Res 1991; 16: 1139–1143.
  • Behan WM, McDonald M, Darlington LG, Stone TW. Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl. Br J Pharmacol 1999; 128: 1754–1760.
  • Santamaria A, Galvan-Arzate S, Lisy V et al. Quinolinic acid induces oxidative stress in rat brain synaptosomes. Neuroreport 2001;12: 871–874.
  • Santamaria A, Jimenez-Capdeville ME, Camacho A, Rodriguez-Martinez E, Flores A, Galvan-Arzate S. In vivo hydroxyl radical formation after quinolinic acid infusion into rat corpus striatum. Neuroreport 2001; 12: 2693–2696.
  • Schurr A, Rigor BM. Quinolinate potentiates the neurotoxicity of excitatory amino acids in hypoxic neuronal tissue in vitro. Brain Res 1993; 617:76–80.
  • Bordelon YM, Chesselet M-F, Nelson D, Welsh F, Erecinska M. Energetic dysfunction in quinolinic acid-lesioned rat striatum. J Neurochem 1997;69: 1629–1639.
  • Kerr SJ, Armati PJ, Guillemin GJ, Brew BJ. Chronic exposure of human neurons to quinolinic acid results in neuronal changes consistent with AIDS dementia complex. AIDS 1998; 12: 355–363.
  • Taber MT, Baker GB, Fibiger HC. Glutamate receptor agonists decrease extracellular dopamine in the rat nucleus accumbens in vivo. Synapse 1996;24: 165–172.
  • Foster AC, Vezzani A, French ED, Schwarcz R. Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci Lett 1984; 48: 273–278.
  • Kerr SJ, Armati PJ, Pemberton LA, Smythe G, Brew BJ. Kynurenine pathway inhibition with 6-chloro-D-tryptophan reduces neurotoxicity of HIV-infected macrophage supernatants [Abstract]. Neurology 1997; 48: A94.
  • Boegman RJ, Jhamandas K, Beninger RJ. Neurotoxicity of tryptophan metabolites. Ann NY Acad Sci 1990; 585: 261–273.
  • Heyes MP. Metabolism and neuropathologic significance of quino-linic acid and kynurenic acid. Biochem Soc Trans 1993; 21: 83–89.
  • Heyes MP, Saito K, Crowley JS et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 1992; 115: 1249–1273.
  • Freese A, Swartz KJ, During MJ, Martin JB. Kynurenine metabolites of tryptophan: implications for neurologic diseases. Neurology 1990; 40: 691–695.
  • Dong-Ruyl L, Sawada M, Nakano K. Tryptophan and its metabolite, kynurenine, stimulate expression of nerve growth factor in cultured mouse astroglial cells. Neurosci Lett 1998; 244: 17–20.
  • Nakagami Y, Saito H, Katsuki H. 3-Hydroxykynureninetoxicity on the rat striatum in vivo. Jpn J Pharmacol 1996; 71: 183-186.
  • Guidetti P. Schwarcz R. 3-Hydroxykynureninepotentiates quinolinate but not NMDA toxicity in the rat striatum. Eur J Neurosci 1999; 11: 3857–3863.
  • Espey MG, Chernyshev ON, Reinhard JJ, Namboodiri MA, Colton CA. Activated human microglia produce the excitotoxin quinolinic acid. Neuroreport 1997; 8: 431–434.
  • Heyes MP, Saito K, Markey SP. Human macrophages convert L-tryptophan into the neurotoxin quinolinic acid. Biochem J 1992; 283: 633–635.
  • Smith DG, Guillemin GJ, Pemberton L et al. Quinolinic acid is produced by macrophages stimulated by platelet activating factor, Nef and Tat. J Neurovirol 2001; 7: 56–60.
  • Guillemin GJ, Kerr SJ, Smythe GA et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem 2001; 78: 1–13.
  • Cunningham AL, Naif H, Saksena N et al. REV infection of macrophages and pathogenesis of AIDS dementia complex: interaction of the host cell and viral genotype. J Leukoc Biol 1997;62: 117–125.
  • Pemberton LA, Kerr SJ, Smythe G, Brew BJ. Quinolinic acid production by macrophages stimulated with IFN-7, TNF-a and 1FN-a. J Interferon Cytokine Res 1997; 17: 589–595.
  • Smith DG, Guillemin GJ, Pemberton LA et al. Quinolinic acid is produced by macrophages stimulated by Paf, Nef and Tat. J Neurovirol 1999; 7: 56–60.
  • Musso T, Gusella GL, Brooks A, Longo DL, Varesio L. Interleukin-4 inhibits indoleamine 2,3-dioxygenase expression in human monocytes. Blood 1994; 83: 1408–1411.
  • Thomas SR, Mohr D, Stocker R. Nitric oxide inhibits indoleamine 2,3-dioxygenase activity in interferon-gamma primed mononuclear phagocytes. J Biol Chem 1994; 269: 14457–14464.
  • Alberati-Giani D, Cesura AM. Expression of the kynurenine enzymes in macrophages and microglial cells: regulation by immune modulators. Amino Acids 1998; 14:251–255.
  • Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, Fuchs D. Degradation of tryptophan in neurodegenerative disorders. Adv Exp Med Biol 1999; 467: 133–138.
  • Baran H, Jellinger K, Deecke L. Kynurenine metabolism in Alzheimer's disease. J Neural Transm 1999; 106: 165–181.
  • Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, Fuchs D. Tryptophan degradation and immune activation in Alzheimer's disease. J Neural Transm 2000; 107: 343–353.
  • Heyes MP, Saito K, Crowley JS et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 1992; 115: 1249–1273.
  • Cooper NR, Bradt BM, O'Barr S, Yu JX. Focal inflammation in the brain: role in Alzheimer's disease. Immunol Res 2000; 21: 159–165.
  • Dickson DW, Lee SC, Mattiace LA, Yen SH, Brosnan C. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 1993; 7: 75–83.
  • Unger JW. Glial reaction in aging and Alzheimer's disease. Microsc Res Tech 1998; 43: 24–28.
  • Fiala M, Liu MW, Reddy S, Graves MC, Vinters HV. Inflammatory response in Alzheimer's disease and amylotrophic lateral sclerosis: role of COX-2-activated macrophages [Abstract]. J Neuroimmunol 2001; 118: 334.
  • Guillemin GJ, Smith DG, Williams K, Smythe GA, Dormont D, Brew BJ.13-Amyloid peptide 1-42 induces human macrophages to produce the neurotoxin quinolinic acid [Abstract]. J Neuroimmunol 2001; 118: 336.
  • Akiyama H, Barger S, Barnum S et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21: 383–421.
  • Eikelenboom P, Rozemuller AJ, Hoozemans JJ, Veerhuis R, van Gool WA. Neuroinflammation and Alzheimer disease: clinical and therapeutic implications. Alzheimer Dis Assoc Disord 2000; 14: 554–S61.
  • Guillemin G, Croitoru J, Dormont D, Brew BJ. Involvement of quinolinic acid in chemokine production and chemokine receptor expression in astrocytes [Abstract]. J Neurovirol 2000; 6: 242.
  • Guillemin GJ, Croitoru J, Smith DG, Dormont D, Brew BJ. Quinolinic acid up-regulates chemokine production and chemokine receptor expression in astrocytes: implications for brain inflam-mation and AIDS [Abstract]. J Neuroimmunol 2001; 118: 119.
  • Xia MQ, Hyman BT. Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. J Neurovirol 1999; 5: 32–41.
  • Lue LF, Rydel R, Brigham EF et al. Inflammatory repertoire of Alzheimer's disease and non-demented elderly microglia in vitro. Glia 2001;35: 72–79.
  • Blasko I, Marx F, Steiner E, Hartmann T, Grubeck-Loebenstein B. TNF-alpha plus IFN-gamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J 1999; 13: 63–68.
  • Nicoll JA, Mrak RE, Graham DI et al. Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol 2000; 47: 365–368.
  • Lawrence CB, Allan SM, Rothwell NJ. Interleukin- lbeta and the interleukin-1 receptor antagonist act in the striatum to modify excitotoxic brain damage in the rat. Eur J Neurosci 1998; 10: 1188–1195.
  • Guillemin GJ, Moore AG, Smith DG et al. Expression of macrophage inhibitory cytokine 1 (MIC-1) in human fetal astrocytes and microglia [Abstract]. J Neuroimmunol 2001; 118: 99
  • Bootcov MR, Bauskin AR, Valenzuela SM et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-b eta superfamily. Proc Natl Acad Sci USA 1997; 94: 11514–11519.
  • Schober A, Bottner M, Strelau J et al. Expression of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in the perinatal, adult, and injured rat brain. J Comp Neurol 2001; 439: 32–45.
  • Wyss-Coray T, Lin C, Yan F et al. TGF-betal promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med 2001; 7: 612–618.
  • Stone DJ, Rozovsky I, Morgan TE, Anderson CP, Finch CE. Increased synaptic sprouting in response to estrogen via an apolipoprotein E-dependent mechanism: implications for Alzheimer's disease. J Neurosci 1998; 18: 3180–3185.
  • Schonknecht P, Pantel J, Klinga K et al. Reduced cerebrospinal fluid estradiol levels are associated with increased beta-amyloid levels in female patients with Alzheimer's disease. Neurosci Lett 2001;307: 122–124.
  • Heron P, Daya S. 17Beta-estradiol protects against quinolinic acid-induced lipid peroxidation in the rat brain. Metab Brain Dis 2000; 15: 267–274.
  • Levin-Allerhand J, McEwen BS, Lominska CE, Lubahn DB, Korach KS, Smith JD. Brain region-specific up-regulation of mouse apolipoprotein E by pharmacological estrogen treatments. J Neurochem 2001;79: 796–803.
  • Riviere S, Gillette-Guyonnet S, Nourhashemi F, Vellas B. Nutrition and Alzheimer's disease. Nutr Rev 1999; 57: 363–367.
  • Refolo LM, Pappolla MA, Malester B et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 2000; 7: 321–331.
  • Maurizi CP. The therapeutic potential for tryptophan and melatonin: possible roles in depression, sleep, Alzheimer's disease and abnormal aging. Med Hypotheses 1990; 31: 233–242.
  • Lee DR, Semba R, Kondo H, Goto S, Nakano K. Decrease in the levels of NGF and BDNF in brains of mice fed a tryptophan-deficient diet. Biosci Biotechnol Biochem 1999; 63: 337–340.
  • Porter RJ, Lunn BS, Walker LL, Gray JM, Ballard CG, O'Brien JT. Cognitive deficit induced by acute tryptophan depletion in patients with Alzheimer's disease. Am J Psychiatty 2000; 157: 638–640.
  • Widner B, Ledochowski M, Fuchs D. Sleep disturbances and tryptophan in patients with Alzheimer's disease. Lancet 2000; 355: 755–756.
  • Feinberg AW. Statins & Alzheimer's. Health News 2000; 6: 1.
  • Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000; 356: 1627–1631.
  • Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors. Arch Neurol 2000; 57: 1439–1443.
  • Farmer JA. Pleiotropic effects of statins. Curr Atheroscler Rep 2000; 2: 208–217.
  • Christen S, Thomas SR, Garner B, Stocker R. Inhibition by interferon-gamma of human mononuclear cell-mediated low density lipoprotein oxidation. Participation of tryptophan metabolism along the kynurenine pathway. J Clin Invest 1994; 93: 2149–2158.
  • Puglielli L, Konopka G, Pack-Chung E et al. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat Cell Biol 2001; 3: 905–912.
  • Hartmann D. From Alzheimer's disease to skin tumors: the catenin connection. Proc Natl Acad Sci USA 2001; 98: 10522–10523.
  • Rudzite V, Jurika E, Jirgensons J. Changes in membrane fluidity induced by tryptophan and its metabolites. Adv Exp Med Biol 1999; 467: 353–367.
  • Olivieri 0, Stanzial AM, Girelli D et al. Selenium status, fatty acids, vitamins A and E, and aging: the Nove Study. Am J Clin Nutr 1994; 60: 510–517.
  • Yoshiike Y, Tanemura K, Murayama 0 et al. New insights on how metals disrupt amyloid beta-aggregation and their effects on amyloid-b eta cytotoxicity. J Biol Chem 2001; 276: 32293–32299.
  • Evans GW, Johnson EC. Effect of iron, vitamin B-6 and picolinic acid on zinc absorption in the rat. J Nutr 1981; 111: 68–75.
  • Pratico D, Clark C, Lee VM, TrojanowskiJ Q, Fitzgerald GA. Increased isoprostane biosynthesis in Alzheimer's disease: Correlation of a specific non-invasive index of lipid peroxidation with disease severity [Abstract]. Neurobiol Aging 2000; 21: S220.
  • Varadarajan S, Yatin S, Aksenova M, Butterfield DA. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J Struct Biol 2000; 130: 184–208.
  • Santamaria A, Santamaria D, Diaz-Munoz M, Espinoza-Gonzalez V, Rios C. Effects of N omega-nitro-L-arginine and L-arginine on quinolinic acid-induced lipid peroxidation. Toxicol Lett 1997;93: 117–124.
  • Jessup W, Mohr D, Gieseg SP, Dean RT, Stocker R. The participation of nitric oxide in cell free- and its restriction of macrophage-mediated oxidation of low-density lipoprotein. Biochim Biophys Acta 1992; 1180:73–82.
  • Ikeda U, Shimpo M, Ikeda M, Minota S, Shimada K. Lipophilic statins augment inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes. J Cardiovasc Pharmacol 2001;38: 69–77.
  • Varnier G, Fedele E, Marchi M, Raiteri M. Intracerebral administration of L-kynurenine decreases N-methyl-D-aspartate receptor-mediated production of cGMP in the cerebellum and hippocampus of unanaesthetized rats subjected to transcerebral microdialysis. Neurosci Lett 1999; 266: 81–84.
  • Thomas SR, Stocker R. Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway. Redox Report 1999; 4: 199–220.
  • Thomas SR, Witting PK, Stocker R. 3-Hydroxyanthranilic acid is an efficient, cell-derived co-antioxidant for alpha-tocopherol, inhibiting human low density lipoprotein and plasma lipid peroxidation. J Biol Chem 1996;271: 32714–32721.
  • Jiang ZG, Piggee C, Heyes MP et al. Glutamate is a mediator of neurotoxicity in secretions of activated HIV-1-infected macrophages. J Neuroimmunol 2001; 117: 97–107.
  • Mena FV, Baab PJ, Zielke CL, Zielke HR. In vivo glutamine hydrolysis in the formation of extracellular glutamate in the injured rat brain. J Neurosci Res 2000; 60: 632–641.
  • Parpura-Gill A, Beitz D, Uemura E. The inhibitory effects of beta-amyloid on glutamate and glucose uptakes by cultured astrocytes. Brain Res 1997;754: 65–71.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.